A clinical trial of tang shen ning for treatment of diabetic nephropathy.

This paper reports the clinical trial of Tang Shen Ning ([symbol: see text], TSN) for treating diabetic nephropathy (incipient and clinical, as divided by Mogensen). The results showed that the total effective rate in treatment group (TSN + western medicine) was 90.0%, and that in the control group (simply with western medicine), 56.7%. TSN plays important roles in decreasing proteinuria and improving renal functions.     

Clinical study on treatment of senile vascular dementia by acupuncture.

63 patients with senile vascular dementia were randomly divided into the treatment group (treated by acupuncture) and the control group (treated with piracetam). The authors observed the changes in the score of Hasegawa's dementia scale (HDS), p300, rheoencephalogram, topographic EEG, superoxide dismutase (SOD) activity in erythrocytes, and lipid peroxide (LPO) level in plasma before and after treatment. The statistical data showed that the total effective rate in the treatment group (80.6%) was significantly higher than that in the control group (25%), and the differences in the observed indexes before and after treatment were significant (P < 0.05 or P < 0.01) in the treatment group but not in the control group (P > 0.05), indicating that the acupuncture treatment was superior in immediate therapeutic effect on senile vascular dementia to drug treatment.     

老年期痴呆患者81例临床分析

目的: 探讨老年期痴呆的临床特征. 方法: 采用简而精神状态检查(MMSE), 哈金斯基缺血指数量表(HIS), 临床痴呆评定量表(CDR), BI评估及回顾性调查. 结果: MMSE,BI均分的比较可见轻度组与中度组之间及中度组与重度组之间,无显著性差异(P＞0.05). 轻度组与重度组之间存非常显著的差异(P＜0.01). BI均分3组之间均有非常显著的差异(P＜0.01). 幻觉、妄想的发生3组间存在较显著差异(P＜0.05);行为紊乱的发生3组间无显著差异(P＞0.05);而既有幻觉、妄想,又有行为紊乱的患者3组间存在显著差异(P＜0.05). 结论: 本组痴呆患者的严重程度与文化程度、年龄并不相关,此结果与报道不同,提示本组痴呆患者较特殊,痴呆严重程度与病程呈非平行关系. 幻觉、妄想及行为紊乱均相对集中痴呆病程早、中期.     

盐酸美金刚片联合多奈哌齐治疗老年痴呆的临床疗效观察

目的探讨盐酸美金刚联合多奈哌齐治疗老年痴呆的临床疗效。方法选择我院2016年7月~2017年3月收治的92例老年痴呆患者为研究对象,随机分为观察组与对照组,每组46例,两组患者均接受常规治疗,对照组在常规治疗基础上加多奈哌齐,观察组在对照组基础上加盐酸美金刚,以两组患者治疗前后简易精神认知量表(MMSE)、蒙特利尔认知评估量表(Mo CA)、日常生活能力量表(ADL)变化评估治疗效果,通过药物副反应量表(TESS)评估安全性,对比两组患者治疗前后内皮素(ET)、脑源性神经营养因子(BDNF)、一氧化氮(NO)变化。结果两组患者治疗后Mo CA、MMSE、ADL评分均较治疗前有明显变化,观察组患者治疗后Mo CA、MMSE、ADL评分较对照组高(P0.05);两组患者神经系统、行为毒性、实验室、心血管系统、其他等各项TESS评分无明显差异(P0.05);两组患者治疗后ET、NO、BDNF较治疗前有明显变化,观察组治疗后ET、NO低于对照组,BDNF较对照组高,差异均有统计学意义(P0.05)。结论盐酸美金刚联合多奈哌齐可改善老年痴呆患者认知功能及日常生活能力,有助于控制NO、ET含量,提高BDNF水平,也具有一定安全性,值得临床推广。     

老年性痴呆患者血清脂质、脂蛋白、载脂蛋白水平变化的研究

目的 探讨脂代谢异常在老年性痴呆病因中的作用.方法 选取46例老年性痴呆患者及50例正常对照者,抽取其静脉空腹血,运用单克隆抗体一免疫酶联吸附法(McAb-ELISA)测定其血清载脂蛋白E(ApoE)含量,同时测定血清中总胆同醇(TC)、甘油三脂(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、极低密度脂蛋白(VLDL-C)、载脂蛋白B(ApoB)和载脂蛋白A(ApoA)含量,并对结果进行比较.结果 ①老年性痴呆组ApoB[(1.72±0.65)mg/L]的水平较对照组[(1.21±0.54)mg/L]明显升高,组间比较差异有显著性(P<0.05);②与对照组[TC、TG、LDL-C、ApoA、ApoE分别为(5.64±2.14)mmol/L、(1.51±1.23)mmol/L、(4.08±0.74)mmol/L、(1.76±0.55mg/L)、(5.21±1.32)mg/L]比较,老年性痴呆组TC[(5.86±2.31)mmol/L]、TG[(1.65±1.21)mmol/L]、LDL-C[(4.10±0.65)mmol/L]、ApoA[(1.85±0.65)mg/L]、ApoE[(5.32±1.45)mg/L]水平较高,但2组间比较差异无显著性(P>0.05);③与对照组比较,老年性痴呆组HDL-C、VLDL-C水平则较低,但2组间比较差异无显著性(P>0.05).结论 脂代谢紊乱在老年性痴呆病因中可能发挥重要作用.     

国产奎硫平与奋乃静治疗老年期精神分裂症对照研究

目的:比较国产奎硫平与奋乃静对老年期精神分裂症的治疗效果及安全性.方法:以奎硫平与奋乃静对66例老年期精神分裂症进行为期8周的对照治疗,采用阳性和阴性症状量表评定疗效,用副反应量表评定不良反应.结果:两组疗效差异无显著性(P>0.05).奎硫平不良反应显著少于奋乃静(P相似文献   

阿立哌唑和利培酮治疗老年期精神分裂症对照研究

目的:比较国产阿立哌唑(商品名:博思清)和利培酮对老年精神分裂症的治疗效果.方法:以阿立哌唑与利培酮对86例老年精神分裂症患者进行为期8周的对照治疗,采用阳性和阴性症状量表(PANSS)评定疗效,用副反应量表(TESS)评定不良反应.结果:阿立哌唑组显效率76.7%,有效率86.0%;利培酮组显效率74.4%,有效率83.7%;不良反应均少而轻微,阿立哌唑主要不良反应为嗜睡,利培酮主要不良反应为锥体外系反应.结论:阿立哌唑和利培酮治疗老年期精神分裂症疗效相当,而且安全性高.     

国产奎硫平与奋乃静治疗老年期精神分裂症对照研究

目的：比较国产奎硫平与奋乃静对老年期精神分裂症的治疗效果及安全性。方法：以奎硫平与奋乃静对66例老年期精神分裂症进行为期8周的对照治疗,采用阳性和阴性症状量表评定疗效,用副反应量表评定不良反应。结果：两组疗效差异无显著性（P〉0.05）。奎硫平不良反应显著少于奋乃静（P〈0.01）。结论：奎硫平是一种安全有效的抗精神病药。     

国产阿立哌唑和利培酮治疗老年期精神分裂症对照研究

目的：比较国产阿立哌唑（商品名：博思清）和利培酮对老年精神分裂症的治疗效果。方法：以阿立哌唑与利培酮对63例老年精神分裂症患者进行为期8周的对照治疗;采用阳性和阴性症状量表评定疗效,用副反应量表评定不良反应。结果：阿立哌唑组显效率71.8%,有效率91.8%;利培酮组显效率70.9%,有效率90.3%;不良反应均少而轻微,阿立哌唑主要不良反应为嗜睡,利培酮主要不良反应为锥体外系反应。结论：阿产哌唑和利培酮治疗老年期精神分裂症疗效相当,而且安全性高。     

CBL教学模式在老年痴呆临床教学中的应用

以病例为基础的学习(CBL)是一种全新的教学模式,其核心是“以病例为先导,以问题为基础,以学生为主体,以教师为主导”.老年痴呆是教学中的一个重点及难点内容,文章结合实践探讨了CBL教学模式的特点、在老年痴呆临床教学中的应用及优势.同时指出应用CBL模式进行临床教学,可显著提高教学质量.     

奥氮平与奋乃静治疗老年痴呆患者精神症状的比较研究

目的:比较奥氮平与奋乃静治疗老年痴呆患者精神症状的疗效及安全性。方法:将60例老年痴呆患者随机分为奥氮平组30例及奋乃静组30例,治疗8周,以BEHAVE-AD量表评估治疗效果,以TESS量表评估患者不良反应。结果:治疗后,两组患者BEHAVEAD评分均较治疗前减分明显(P<0.01),但两组患者间治疗前后BEHAVE-AD减分值差异无统计学意义(P>0.05)。不良反应奥氮平组患者多见嗜睡,食欲增加,体重增加;奋乃静组多见椎体外系反应。结论:奥氮平与奋乃静治疗老年痴呆精神症状疗效相当,且不良反应均较少。     

尼莫地平治疗老年期痴呆的临床观察

目的 :对照观察尼莫地平与脑复康治疗老年期痴呆患者 180例的临床疗效。方法 :将 180例老年期痴呆患者随机分为 2组 ,治疗组口服尼莫地平 ,对照组口服脑复康。结果 :治疗后患者简易智力状态检查量表 (MMSE)评分提高 ,日常生活能力量表 (ADL)评分下降 (P <0 .0 1)。治疗组显效率为 30 % ,总有效率为 74 .4 %。对照组显效率为 2 2 .2 % ,总有效率为 62 .2 % ,两组间比较有统计学意义 (P <0 .0 1)。结论 :改善脑循环是尼莫地平治疗老年期痴呆的机理之一 ,从而提高患者认知功能与生活能力 ,疗效肯定 ,使用安全 ,未见明显副作用     

Clinical observation and mechanism study on treatment of senile dementia with Naohuandan

Objective: To observe the therapeutic effect and mechanism of Naohuandan (NHD) in treating senile dementia (SD).Methods: Clinical study: Fifty-eight patients with SD, whose diagnosis conforms to the Diagnostic Standard of DSM-IV issued by American Association of Psychiatry, were enrolled and randomly assigned into two groups. The 30 patients in the treated group were treated with NHD, 4 capsules each time, 3 times daily. The 28 patients in the control group were treated with Piracetam, 1. 6 g each time, 3 times daily. The therapeutic course for both groups was 3 months. The therapeutic efficacy was estimated and compared by comprehensive scores of memory and cognition, scores of Mini-mental State Examination (MMSE) and Activities of Daily Living (ADL). Experimental study: Rats were divided into the control group, the model group and the high-dosage and low-dosage NHD treated groups. The protective effect of NHD on the per-oxidative damage of hippocampal neurons in β-amyloid protein induced SD model was observed and the related criteria were determined.Results: Clinical study showed that both NHD and Piracetam could improve the clinical symptoms of patients, the two medicines showing insignificant difference in total effective rate. But NHD was better in elevating MMSE score and lowering ADL score in patients than Piracetam (P< 0.05 andP<0.01). Experimental study showed that (1) 24 and 72 hrs after modeling, the activity of SOD and GSH were lower and the level of MDA higher in the model group than those in the control group (P<0.05 orP<0. 01). Compared with the model group at the corresponding time points, in the high-dosage NHD group, SOD and GSH were higher, MDA was lower (P<0. 05 orP<0. 01); but in the low-dosage NHD group, SOD at the 72th hr was higher (P<0.05) and MDA at 24th and 72th hrs was lower (P<0.01). And most of the criteria in the high-dosage NHD group was improved better than that in the low-dosage NHD group. (2) The survival rates of neurons in various groups were not different significantly (P>0.05) 24 hrs after modeling, but that in the high-dosage NHD group was significantly higher than that in the model group (P<0.01) and in the low-dosage NHD group 72 hrs after modeling(P<0.05).Conclusion: NHD is an effective Chinese herbal preparation for treatment of SD, and its mechanism is related with its inhibition on peroxidative injury and protection on neurons. Supported by the Research Fund from Guangdong Provincial Administration of TCM (No. A002003002)     

老年性痴呆并发肺部感染分析

目的 探讨老年性痴呆患者肺部感染的高发因素及肺部感染对预后的影响,寻求降低肺部感染率的方法.方法分析2003-2008年间我院门诊及住院老年性痴呆患者196例,采用卡方检验法分析部感染率与患者年龄、病种、病情、基础疾病及预后的关系. 结果 高龄、病情重、原有糖尿病、心脏病、肿瘤、免疫系统疾病及中风史患者,其肺部感染率明显升高,并发肺部感染的患者病死率明显升高. 结论 控制肺部感染可有效提高老年性痴,呆救治成功率.     

曲唑酮治疗老年苯二氮卓类药物依赖患者临床观察

目的 探讨曲唑酮对老年苯二氮卓类药物(BZD)依赖患者替代治疗的疗效及对认知功的影响.方法 对51例老年BZD依赖患者采用剂量快速递减、曲唑酮替代疗法,14d内停用BZD,之后睡前顿服曲唑酮,连服6个月.采用匹兹堡睡眠质量指数(PSQJ)量表和副反应量表(TESS)评定临床疗效和不良反应.选用韦氏成人智力量表( WAIS-RC)、韦氏成人记忆量表(WMS-RC)评定认知功能.疗效和不良反应于治疗前后评定;认知功能于治疗前后各评定1次.结果 PSQJ总分[(13.17 ±3.70)分,(11.05±3.48)分]、睡眠质量[(2.36±0.33)分,(1.91 ±0.29)分]、睡眠障碍、日间功能障碍分疗后低于疗前(P＜0.05),其他成份分无差异.曲唑酮副反应少而轻,更无依赖发生.认知功能中的知识、算术、数字符号、木块拼图、长时记忆、短时记忆、即刻记忆及记忆商数分方面疗前均低于疗后(P＜0.05).结论 曲唑酮可作为老年失眠患者的理想药物.     

安理申联合恩必普和金纳多治疗老年痴呆68例临床疗效观察

目的:探索安理申联合恩必普和金纳多治疗老年痴呆临床疗效。方法:将老年痴呆患者68例进行随机分组,对照组34例,观察组34例。对照组患者单纯用安理申治疗,观察组患者应用安理申联合恩必普和金纳多,采用日常能力评分(ADL)以及简易智能状态量表(MMSE)进行测评两组患者组治疗前及治疗3、6个月的疗效。结果:观察组患者治疗后3个月和6个月的行为能力及认知功能均改善且明显好于对照组。ADL评分,观察组患者由治疗前的(18.65±5.67)分降为治疗后3个月的(10.26±6.37)分,治疗后6个月的(8.87±6.04)分,各时间比较,差异明显(P<0.05);对照组患者由治疗前的(18.59±4.98)分,降为治疗后3个月的(14.87±6.54)分,治疗后6个月的(12.01±6.28)分,效果不显著;MMSE评分在治疗后均呈上升趋势,治疗组差异明显(P<0.05),对照组效果不明显。结论:对老年痴呆患者采用安理申联合恩必普和金纳多治疗,临床效果明显优于单纯采用安理申的疗效。